JOURNAL LOPINIONBusiness Directories,Company Directories

Company Name: Corporate Name:	JOURNAL LOPINION
Company Title:
Company Description:
Keywords to Search:
Company Address:	402 Rue Lindsay,DRUMMONDVILLE,QC,Canada
ZIP Code: Postal Code:	J2B
Telephone Number:	8194753334
Fax Number:	5148438600
Website:
Email:
USA SIC Code(Standard Industrial Classification Code):	140650
USA SIC Description:	MAGAZINES & NEWSPAPERS
Number of Employees:
Sales Amount:	Less than $500,000
Credit History: Credit Report:	Very Good
Contact Person:
Remove my name

Company Directories & Business Directories

copy and paste this google map to your website or blog!

Press copy button and paste into your blog or website.
(Please switch to 'HTML' mode when posting into your blog. Examples:
WordPress Example, Blogger Example)

Input Form:Deal with this potential dealer,buyer,seller,supplier,manufacturer,exporter,importer

(Any information to deal,buy, sell, quote for products or service)

Previous company profile:
JOYAL ADAM LANDRY NOTAIRES
JOYAL & ADAM NOTAIRES
JOYAL ADAM & LANDRY

Next company profile:
JOURNAL LEXPRESS
JOUBERT, DIANE
JONQUILLE VANNERIE

Company News:

The New England Journal of Medicine | Research Review Articles on . . .
The New England Journal of Medicine (NEJM) is a weekly general medical journal that publishes new medical research and review articles, and editorial opinion on a wide variety of topics of
New England Journal of Medicine
The New England Journal of Medicine publishes high-quality medical research, reviews, and opinions to advance medical science and improve patient care
Structured Exercise after Adjuvant Chemotherapy for Colon Cancer
In this phase 3, randomized trial conducted at 55 centers, we assigned patients with resected colon cancer who had completed adjuvant chemotherapy to participate in a structured exercise program
First-Line Camizestrant for Emerging - The New England Journal of Medicine
Mutations in ESR1 are the most common mechanism of acquired resistance to treatment with an aromatase inhibitor plus a cyclin-dependent kinase 4 and 6 (CDK4 6) inhibitor for advanced breast cancer
Tarlatamab in Small-Cell Lung Cancer after Platinum-Based Chemotherapy
Tarlatamab, a bispecific delta-like ligand 3–directed T-cell engager immunotherapy, received accelerated approval for the treatment of patients with previously treated small-cell lung cancer
Tezepelumab in Adults with Severe Chronic Rhinosinusitis with Nasal . . .
Treatment with tezepelumab has been effective for sinonasal symptoms in patients with severe, uncontrolled asthma and a history of chronic rhinosinusitis with nasal polyps, but its efficacy and saf
Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist, in Early . . .
Orforglipron is a small-molecule, nonpeptide glucagon-like peptide-1 (GLP-1) receptor agonist in clinical development for type 2 diabetes and weight management Additional data on the efficacy and
Zongertinib in Previously Treated - The New England Journal of Medicine
Innovative oral targeted therapies are warranted for patients with human epidermal growth factor receptor 2 (HER2)–mutant non–small-cell lung cancer (NSCLC) Zongertinib is an oral
Tolebrutinib in Nonrelapsing Secondary Progressive Multiple Sclerosis
Throughout the course of multiple sclerosis, gradually progressive neurologic impairment can occur, which has been called disability accrual Current disease-modifying therapies for multiple sclero